[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].

Abstract excerpt

Since several years, the perception of lung cancer has considerably evolved. Indeed, we have proceeded from a simple classification based on histology to a molecular dismemberment, with a lot of subtypes of tumors according to there molecular alteration profile. Mutations of the EGFR receptor define so a group of cancers particularly sensitive to EGFR tyrosine kinase inhibitors (TKI). Gefitinib has shown its...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Crizotinib
• Share to Gefitinib
• Share to Gene Amplification